Navigation Links
Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™
Date:7/5/2011

LOS ANGELES, July 5, 2011 /PRNewswire/ -- NeuroSigma, a Los Angeles-based neuromodulation company, today announced that a recent Phase I clinical trial revealed that external Trigeminal Nerve Stimulation (eTNS™) increased regional cerebral blood flow in brain regions associated with depression and mood regulation.  eTNS™ was shown to be a potential therapy for depression, with significant reductions in depression severity during the 8-week adjunctive treatment period.  These encouraging results have led to a Phase II double-blind trial with expected completion later this year.

(Photo: http://photos.prnewswire.com/prnh/20110705/NY29679 )

eTNS™ and Depression

Trigeminal Nerve Stimulation (TNS) is a promising new therapy for the treatment of major depression without the typical side effects of antidepressants.  TNS was invented by researchers at UCLA and is exclusively licensed to NeuroSigma.  

In June of last year, UCLA investigators reported preliminary results from the first five patients of the open-label Phase I TNS feasibility trial, noting a 70% reduction in symptom severity over the 8-week acute phase of treatment, resulting in an 80% remission rate. (http://newsroom.ucla.edu/portal/ucla/non-invasive-therapy-significantly-169741.aspx).  

Last month, at the New Clinical Drug Evaluation Unit (NDCEU) 51st Annual Meeting in Boca Raton, Florida, Ian Cook, M.D., the Joanne and George Miller Family Chair in Depression Research at the Semel Institute at UCLA, and a medical advisor to NeuroSigma, presented additional data from four new subjects enrolled in this Phase I trial, which included functional neuroimaging PET data.  Cook noted that "with just brief exposure to eTNS™, significant increases in regional cerebral blood flow were detected in the anterior cingulate and the dorsomedial frontal cortical regions, which are brain regions implicated in mood disturbances – most notably the anterior cingulate gyrus, inferior frontal gyrus, medial and middle frontal gyri and the parietotemporal cortex."  Cook added, "These findings of a potential mechanism of action support our original hypothesis that electrical stimulation of the trigeminal nerves, located in facial skin tissue, can provide a very safe and effective means to send signals to key structures deep in the brain, thus providing a high-bandwidth pathway to the brain without current penetrating directly through the skull."  These four subjects realized a 44% reduction in their HDRS depression severity score during the 8-week treatment period.

"We would like to congratulate Drs. Cook, Lara Schrader, Daniel Silverman, Christopher DeGiorgio, and the rest of the UCLA team for these impressive PET findings," said Leon Ekchian, Ph.D., President and CEO of NeuroSigma.  "These results have identified a potential mechanism of action of TNS, should facilitate discussions with potential strategic partners and the investment community and have provided us with clues as to which indications to add to our TNS pipeline.  In addition to depression, we have clinical trials underway for epilepsy and post-traumatic stress disorder (PTSD) and expect to initiate clinical trials for additional indications in the near future," added Ekchian.

"We wish to especially thank Dr. John Mazziotta, Chairman of the UCLA Department of Neurology and Director of the UCLA Brain Mapping Center, which is widely regarded as the singular facility for neuroimaging in the world, for his support in making this breakthrough possible," said Lodwrick M. Cook, Chairman of NeuroSigma.

UCLA investigators have commenced the twenty-subject, double-blind, Phase II clinical trial, with funding provided by NeuroSigma, to further assess the safety and efficacy of eTNS™ as a potential adjunctive therapy for the treatment of depression.  The trial began in February with a target completion date in late 2011.

Depression Background

Over 18 million Americans suffer from major depression, which affects mood, sleep, memory, concentration and raises thoughts of suicide.  It is the current leading cause of disability for 15-44 year olds.  The World Health Organization projects that after heart disease, major depression will be the most significant cause for disability in the world by 2020.

Antidepressant drugs are the most common therapy for depression, however they can have major side effects, including obesity, sexual dysfunction, fatigue, drowsiness and nausea.  Furthermore, prescribing antidepressants typically entails a trial and error selection process with only 30% of patients reaching remission with their first antidepressant trial.  Many patients abandon treatment before effectiveness can be determined.

NeuroSigma is developing two embodiments of TNS: eTNS™ and sTNS™ (subcutaneous electrodes).  Once approved by regulatory agencies, patients who respond well to eTNS™ can opt to switch to the implantable sTNS™ system.  

CAUTION: Both eTNS™ and sTNS™ systems are investigational devices and at this time are limited by United States law for investigational use only.

About NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice.  Currently we have a specific focus on neuromodulation.  NeuroSigma employs two therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed significant intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS.  For more information about NeuroSigma, visit our website at http://www.neurosigma.com


'/>"/>
SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
3. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
4. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
5. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
6. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
7. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
10. Potential Early Warning System for Lung Cancer Identified
11. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Spain , Dec. 2, 2016 In ... natural sources apart from those derived from C. sativa, ... the Universita` di Napoli Federico II , the ... created the first comprehensive, critical, integrated and unified inventory ... The article focuses on the remarkable chemical and ...
(Date:12/2/2016)... , Dec. 2, 2016  Eli Lilly and ... financial guidance for 2017 and provide updated financial guidance ... also conduct a conference call on that day with ... company,s financial guidance. The conference call will ... general public can access a live webcast of the ...
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... California, will be included in the 2016 “Guide to America’s Top Plastic Surgeons” ... on the amalgamation of their education, experience, and professional associations. , One ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference ... and Spa in Honolulu, offering local frontline clinicians the opportunity to extend their ... The demand for supplemental training related to pain management has surged dramatically in ...
Breaking Medicine News(10 mins):